Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
